Robert M. Aris, MD

Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
CB 7020, Room 4131, Bioinformatics Building
130 Mason Farm Rd
Chapel Hill, NC 27599


• (1976-1980) Jacksonville University, BA, Biology and Chemistry Valedictorian (straight As for all classes)
• (1980-1984) Vanderbilt University, MD
• (1984-1987) University of Colorado, Denver Resident, Internal Medicine
• (1987-1990) University of California, San Francisco: Fellowships, Pulmonary and Critical Care Medicine and the Cardiovascular Research Institute

• (2013-Present) Pulmonary Consultant, Central Carolina Hospital Sanford, NC
• (2011-2014) Pulmonary Consultant, Rex Hospital, Raleigh, NC
• (2011-Present) Pulmonary Consultant, UNC Physicians Network, Sanford, NC
• (8/2010-Present) Professor of Medicine, University of North Carolina
• (2002-2012) Co-Director, Pulmonary Hypertension Program UNC
• (2000-2010 ) Director, Lung Transplantation Immunology Laboratory
• (1999-2010) Associate Professor of Medicine (with tenure), University of North Carolina
• (1998-2004) Medical Director, Lung Transplantation Program, UNC
• (1994-2004) Director, Inpatient Pulmonary Medicine Service, UNC
• (1993-1999) Assistant Professor of Medicine, The University of North Carolina
• (1990-1993) Assistant Professor of Medicine, University of California, San Francisco, Chief, Chest Clinic, San Francisco General Hospital, UCSF

Research Interest

His research interests includes clinical and translational research in the fields of Lung transplantation, cystic fibrosis and Pulmonary hypertension.

Scientific Activities

• Presidents Scholarship (full academic scholarship), 1976-80; given to one graduating senior from each high school in Jacksonville FL based on academic performance
• Phi Kappa Phi Scholarship, 1980
• Biology Student of the Year, 1979
• Chemistry Student of the Year, 1980
• American Tae Kwon Do Association Black Belt, 1st degree, decided, 1980
• Alpha Omega Alpha Medical Honor Society, 1983; eligible to graduates in the top 15% of the class after an affirmative vote by our peers
• Listed in Guide to Americas Top Physicians by Consumers Research Council of America, 2005. 2011, 2013, 2014
• Madisons Whos Who, 2003-present
• Covington’s Whos Who 2014

• American Thoracic Society
• North Carolina Thoracic Society
• American Society of Transplantation
• International Society of Heart and Lung Transplantation
• Alpha Omega Alpha


Journal Articles

1. Aris R, Christian D, Sheppard D, Balmes J. Acid fog induced bronchoconstriction: the role of hydroxymethanesulfonic acid. Am Rev of Respir Dis. 1990; 141: 546-551. doi: 10.1164/ajrccm/141.3.546
2. Aris R, Christian D, Sheppard D, Balmes J. The effects of sequential exposure to acidic fog and ozone on pulmonary function in exercising subjects. Am Rev of Resp Dis. 1991; 143: 85-91. doi: 10.1164/ajrccm/143.1.85
3. Aris R, Christian D, Sheppard D, Balmes J. Lack of bronchoconstrictor response to sulfuric acid aerosols and fogs. Am Rev Resp Dis. 1991; 143: 744-750. doi: 10.1164/ajrccm/143.4_Pt_1.744
4. Aris R, Christian D, Finkbeiner W, Balmes J . The effects of nitric acid vapor alone, and in combination with ozone, on healthy volunteers. Am Rev Resp Dis. 1993; 148: 965-973. doi: 10.1164/ajrccm/148.4_Pt_1.965
5. Aris R, Christian D, Hearne P, Kerr K, Finkbeiner W, Balmes J . Ozone-induced airway inflammation in human subjects as assessed by airway lavage and biopsy. Am Rev Resp Dis. 1993; 148: 1363-1372. doi: 10.1164/ajrccm/148.5.1363
6. Erle D, Brown T, Christian D, ArisR. Lung epithelial lining fluid T cell subsets have distinct patterns of 7 and 1 integrin expression. Am J Respir Cell Mol Bio. 1994; 10: 237-242. doi: 10.1165/ajrcmb.10.3.7509610
7. Aris R, Christian D, Hearne P, et al. Methacholine responsiveness is not associated with ozone-induced decrements in FEV1. Chest. 1995; 107: 621-628.
8. Egan TM, Thompson J, Detterbeck F, et al. Effect of size (mis)matching in clinical double-lung transplantation. Transplantation. 1995; 59: 707-713.
9. Balmes J, Chen L, Scannell C, et al. Ozone-induced decrements in FEV1 and FVC do not correlate with measures of inflammation. Am J RespCrit Care Med. 1996; 153: 904-909. doi: 10.1164/ajrccm.153.3.8630571
10. Aris R, Neuringer I, Egan T, Weiner M, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest. 1996; 109: 1176-1183. doi: 10.1378/chest.109.5.1176
11. Scannell C, Chen LL, Aris RM, et al. Greater ozone-induced inflammatory responses in subjects with asthma. Am J RespirCrit Care Med. 1996; 154: 24-29. doi: 10.1164/ajrccm.154.1.8680687
12. Donaldson S, Novotony D, Paradowski L and ArisRM. Acute and chronic lung allograft rejection during pregnancy. Chest. 1996; 110: 293-296. doi: 10.1378/chest.110.1.293
13. Aris RM, Maia D, Neuringer I, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med. 1996; 154: 1712-1717. doi: 10.1164/ajrccm.154.6.8970360
14. Stang M, Hinderliter A, Gott K, Paradowski L, Aris RM. Atrial anastomotic thrombus causing reversible neurologic deficits after lung transplantation. Transplantation. 1996; 62: 693-695.
15. Aris RM. Osteoporosis in patients undergoing lung transplantation. Chest. 1997; 111: 257-258.
16. Aris RM, Gilligan P, Neuringer I, Gott K, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997; 155: 1699-1704. doi: 10.1164/ajrccm.155.5.9154879
17. Fitzsimons E, Aris RM, and Patterson R. Recurrence of ABPA in the post-transplant lungs of a cystic fibrosis patient. Chest. 1997; 112: 281-283. doi: 10.1378/chest.112.1.281
18. Balmes J, Aris R, Chen L, et al. Effects of ozone on normal and potentially sensitive subjects. Part I: airway inflammation and respon-siveness to ozone in normal and asthmatic subjects. Research Report-Health Effects Institute. 1997; 78: 1-37.
19. Aris R, Renner J, Winders A, et al. Increased fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Int Med. 1998; 128: 186-193. doi: 10.7326/0003-4819-128-3-199802010-00004
20. Aris R, Barbers R, Barst R, et al. International guidelines for the selection of lung transplant candidates. Am J RespirCrit Care Med. 1998; 158: 335-339. doi: 10.1164/ajrccm.158.1.15812
21. Neuringer I, Mannon R, Coffman T, Burns K, Yankaskas J, Aris R. Immune cells in the mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Bio. 1998; 19: 379-386. doi: 10.1165/ajrcmb.19.3.3023m
22. Egan T, Detterbeck F, Mill M, et al. Lung transplan-tation for cystic fibrosis: effective and durable therapy in a high-risk group. Ann ThoracSurg. 1998; 66: 337-346. doi: 10.1016/S0003-4975(98)00496-2
23. Aris R, Lester G, OntjesD. Bone loss physiology in the chronically critically ill. Chest. 1998; 114: 954-955.
24. Aris R, Lester G, Dingman S, Ontjes D. Altered calcium homeostasis in adults with cystic fibrosis. Osteoporosis International. 1999; 10(2): 102-108.
25. Neuringer I, Walsh S, Mannon R, Gabriel S, Aris R. Enhanced T-cell cytokine gene expression in mouse airway obliterative bronchiolitis. Transplantation. 2000; 69: 399-405.
26. Aris R, Lester G, Renner J, et al. Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation. Am J Respir Crit Care Med. 2000; 162: 941-946. doi: 10.1164/ajrccm.162.3.2002051
27. Aris R, Stevens A, Ontjes D, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med. 2000; 162(5): 1674-1678. doi: 10.1164/ajrccm.162.5.2002100
28. Yankaskas J, ArisR. Outpatient Care of Cystic Fibrosis Patient after Lung Transplantation. CurrOpin in Pulm Med. 2000; 6(6): 551-557.
29. Gilbey J, Chalermskulrat W, Aris R. Aspergillus endocarditis in a lung transplant recipient: case report and review of the transplant literature. Annals of Transplantation. 2000; 5(3): 48-53.
30. Lark R, Lester G, Ontjes D, et al. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. Am J Clin Nutr. 2001; 73(3): 602-606.
31. Aris R, Routh J, LiPuma J, Heath D, Gilligan P. Lung transplantation for cystic fibrosis patients with Burk-holderia cepacia complex: survival linked to genomovar type. Am J RespirCrit Care Med. 2001; 164: 2102-2106. doi: 10.1164/ajrccm.164.11.2107022
32. Aris R, Ontjes D, Buell H, et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporosis Int. 2002; 13(2): 151-157.
33. Heath D, Hohneker K, Curriker C, et al. A six-year molecular analysis of Burkholderiacepacia isolates among cystic fibrosis patients at a referral center for lung transplantation. J ClinMicrobiol. 2002; 40(4): 1188-1193. doi: 10.1128/JCM.40.4.1188-1193.2002
34. Neuringer I, Aris R, Burns K, Bartolotta T, Chalermskulrat W, Randell S. Epithelial Cell Kinetics in Mouse Tracheal Allografts. Am J Transplantation. 2002; 2: 410-419. doi: 10.1034/j.1600-6143.2002.20503.x
35. Aris R, Walsh S, Chalermskulrat W, Hathwar V, Neuringer I. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J RespirCrit Care. 2002; 166(3): 417-422. doi: 10.1164/rccm.2102106
36. Aris R. Pathogenesis of CF bone disease. Ped Pulmonol. 2002; 24: 177-178.
37. Egan T, Detterbeck F, Mill M, et al. Long term results of lung transplantation for cystic fibrosis. Eur J CardiothoracSurg. 2002; 22(4): 602. doi: 10.1016/S1010-7940(02)00376-7
38. Aris R. Complications after lung transplantation: clues to diagnosis. J Crit Illness. 2003; 18(2): 52-53.
39. Chalermskulrat W, Neuringer I, Brickey J, et al. Hierarchical Contributions of Allorecognition Pathways in Chronic Lung Rejection. Am J Respir Crit Care Med. 2003; 167: 999-1007. doi: 10.1164/rccm.200209-1099OC
40. Chalermskulrat W, Neuringer I, Schmitz J, Gurka M, Randell S, Aris R. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest. 2003; 123: 1825-1831. doi: 10.1378/chest.123.6.1825
41. Brown S, Ontjes D, Lark R, et al. Short-term calcitriol administration improves calcium homeostasis in adults with CF. Osteoporosis Int. 2003; 14(5): 442-449. doi: 10.1007/s00198-002-1331-x
42. Aris R, Brown S, Ontjes D, Chalermskulrat W, Neuringer I, Lester G. Carboxylated Osteocalcin Levels in Cystic Fibrosis. Am J Respir Crit Care Med. 2003; 168(9): 1129. doi: 10.1164/ajrccm.168.9.950
43. Aris R, Lester G, Camaniti M, et al. Efficacy of Alendronate in Cystic Fibrosis Adults with Low Bone Density. Am J RespirCrit Care Med. 2004; 169: 77-82. doi: 10.1164/rccm.200307-1049OC
44. Hecker T, Aris R. Management of osteoporosis in adults with cystic fibrosis. Drugs. 2004; 64 (2): 133-147.
45. Charlermskulrat W, Neuringer I, Park R, et al. PX3.102, a Novel Chinese Herb Extract, Diminishes Chronic Airway Allograft Rejection. Transplantation. 2004; 78(1): 158-161.
46. Tullis E, Aris R. Timing of Referral for Lung Transplant: Coordination Between the CF Center and Lung Transplantation Centers. Ped Pulmonol. 2004; 27: 176-177.
47. Aris R, Lester G, Ontjes D. Treatment of bone disease in cystic fibrosis. Cur Opin in Pulm Med. 2004; 10(6): 524-530.
48. Aris R, Donohue J, Ontjes D. Inhaled corticosteroids and fracture risk: Having our cake and eating it too. Chest. 2005; 127(1): 5-7. doi: 10.1378/chest.127.1.5
49. Aris R, Guise T. Cystic Fibrosis and Bone Disease: Are We Missing a Genetic Link. EurRespir J. 2005; 25(1): 9-11. doi: 10.1183/09031936.04.00125804
50. Aris R, Merkel P, Bachrach L, et al. Review of a consensus conference report: Guide to Bone Health and Disease in Cystic Fibrosis. J Clin Endocrinol Metab. 2005; 90(3): 1888-1896.
51. Neuringer I, Charlermskulrat W, Aris R. Obliterative Bronchiolitis: Basic mechanisms of chronic lung rejection. J Heart Lung Transplant. 2005; 24: 3-19.
52. Van Deventer H, Oconnor W, Brickey W, Aris R, Ting J, Serody J. Chemokine Receptor 5 (CCR5) Promotes Pulmonary Metastasis. Cancer Res. 2005; 65(8): 3374-3379. doi: 10.1158/0008-5472.CAN-04-2616
53. Neuringer I, Chalermskulrat W, Aris R. Special problems in long-term survivors of lung transplantation. Pulmonary and Critical Care Update (PCCU). 19(11).
54. Neuringer I, Sloan J, Chalermskulrat W, et al. Calcineurin Inhibitor Effects on Growth and Phenotype of Human Airway Epithelial Cells In Vitro. Am J Transplant. 2005; 5(11): 2660-2670. doi: 10.1111/j.1600-6143.2005.01071.x
55. Charlermskulrat W, BrickeyW, Neuringer I, et al. Combined donor specific transfusion and anti-CD154 therapy achieves airway allograft tolerance. Thorax. 2006; 61(1): 61-67. doi: 10.1136/thx.2005.047316
56. Snell G, Valentine V, Vitulo P, et al. Everolimus vs azathioprine as adjunctive immunosupressive therapy to inhibit the decline of pulmonary function in stable lung or heart/lung transplant recipients: 12 and 24-Month Results of an International, Randomized, Double-Blind Study. Am J Transplant . 2006; 6: 169-177. doi: 10.1111/j.1600-6143.2005.01134.x
57. Dua S, Chalermskultat W, Miller M, Landers M, Aris R. Bilateral Pseudomonas endopthalmitis after lung transplantation. Am J Transplant. 2006; 6: 219-224. doi: 10.1111/j.1600-6143.2005.01133.x
58. Kovarik J, Snell G, Valentine V, et al. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant. 2006; 25(4): 440-446.
59. Chalermskulrat W, Sood N, Neuringer I, et al. Non tuberculous Mycobacteria in End-Stage Cystic Fibrosis: Implications for Lung Transplantation. Thorax. 2006; 61(6): 507-513. doi: 10.1136/thx.2005.049247
60. Dellon E, Morgan D, Mohanty S, Davis K, Aris R. High Incidence of Bezoars in Cystic Fibrosis Patients after Lung Transplantation. Transplantation. 2007; 81(8): 1141-1146. doi: 10.1097/
61. Kennedy M, Coakley R, Donaldson S, et al. Burkholderia Gladioli: Five-year Experience in a CF Referral and Lung Transplantation Center. J Cystic Fibrosis. 2007; 6(4): 267-273. doi: 10.1016/j.jcf.2006.10.007
62. Clines G, Kingsley L, McKibbin C, Gabriel S, Aris R. CF bone disease: Is mutant CFTR really the culprit. Ped Pulmonology. 2007; 188-189.
63. Neuringer I, Medaiyese A, McNeillie P, Budd S, Aris R. New Insights into Lung Allograft Rejection. CurrResp Med Rev. 2008; 4: 40-51.
64. Wheless S, Gulley M, Raab N, et al. Post Transplantation Lymphoproliferative Disorder: Epstein Barr Viral Loads, HLA A3, and Survival. Am J RespirCrit Care Med. 2008; 178(10): 1060-1065.
65. Aris R. Update on Bone Mineralization in CF. Pediatric Pumonol. 2008; (Supp 31): 173-175.
66. Ford HJ, Andreoni K, Aris RM. Screening for Porto pulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. Am J Respir Crit Care Med. 2009; 180(4): 378.
67. Sermet I, Castanet M, Retsch G, Aris R. Update on Bone Disease in CF with a Focus on Children. Paediatr Respir Rev. 2009; 10(3): 134-142. doi: 10.1016/j.prrv.2009.05.001
68. Neuringer I, Noone P, Cicale R, Davis K, Aris R. Managing complications following lung transplantation. Expert Reviews in Respiratory Medicine. 2009; 3(4): 403-423. doi: 10.1586/ers.09.27
69. Lommatszch S, Aris RM. The Genetics of Cystic Fibrosis. Semin Respir Crit Care Med. 2009 ; 30(5): 531-538.
70. Sparks A, McGee S, Boone C, Neuringer I, Jones S, Aris R. Old Bones in Young Bodies: The Tale of Cystic Fibrosis. Curr Opin Endocrinol Diabetes Obes. 2009; 16(6): 407-414. doi: 10.1097/MED.0b013e3283329b16
71. Hall W, Sparks A, Aris R. Vitamin D Deficiency in Cystic Fibrosis. Int J Endocrinol. 2010; 2010: 218691. doi: 10.1155/2010/218691
72. Palmer S, Limaye A, Banks M, et al. Extended Valganciclovir Prophylaxis To Prevent Cytomegalovirus After Lung Transplantation: A Randomized Controlled Trial. Ann Int Med. 2010; 152(12): 761-769. doi: 10.7326/0003-4819-152-12-201006150-00003
73. Neuringer I, Aris RIs it time to prospectively match human leukocyte antigen proteins for lung transplantation?. Transplantation. 2010; 90(8): 823-824. doi: 10.1097/TP.0b013e3181f2c99e
74. Sermet I, Bianchi M, Garabedian M, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011; 10(Supp 2): S16-S23. doi: 10.1016/S1569-1993(11)60004-0
75. Aris R. Does transplantation alter vitamin D management. Ped Pulmonol. 2011; suppl (34): 111-113.
76. Goralski J, Aris R. Achieving Optimal Bone Health in Cystic Fibrosis: Ready for Prime Time? Therapy. 2011; 8: 587-590.
77. Judson M, Highland K, Kwon S, et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(2): 139-145.
78. Hall W, Aris R. Images in Pulmonary Medicine: Epidural Pneumatosis and Diffuse Soft Tissue Free Air As a Complication of Diabetic Ketoacidosis. Am J Resp Crit Care Med. 2012; 185(4): e5. doi: 10.1164/rccm.201105-0916IM
79. Tangpricha V, Kelly A, Stephenson A, et al. The Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012.
80. Budd S, Aris RM, Funkhouser W, Cicale B, Davis WK, Neuringer IP. Increased Mannose Binding Lectin Levels Are Associated with Bronchiolitis Obliterans after Lung Transplantation. Transplantation Resp Res. 2012; 413(1): 56. doi: 10.1186/1465-9921-13-56
81. Fares W, Blanchard S, Stouffer G, et al. Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. Can Respir J. 2012; 19(4): 261-266.
82. Fares W, Ford H, Ghio A, Aris R. Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of bio markers in pulmonary hypertension. Pulm Circ. 2012; 2: 477-482. doi: 10.4103/2045-8932.105036
83. Lobo L, Aris R, Schmitz J, Neuringer I. Donor Specific Antibodies are associated with Antibody Mediated Rejection, Acute Cellular Rejection, BOS and Cystic Fibrosis after Lung Transplantation. J Heart Lung Transplant. 2013; 32(1): 70-77. doi: 10.1016/j.healun.2012.10.007
84. Lobo L, Aris R, Norfolk SG, et al. Rituximab associated Progressive Multifocal Leukoencephalopathy After Lung Transplantation. Transplantation J Heart Lung Transplant. 2013 ; 32(7): 752-753. doi: 10.1016/j.healun.2013.04.007
85. Lobo LJ, Aris R. Does Ischemia Reperfusion Injury After Transplantation Damage Native. Organs Transplantation.
86. Meyer K, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Resp Journal. doi: 10.1183/09031936.00107514
87. McNeillie P, Hammett C, Olegessi O, et al. Inhaled Cyclosporine Alters Airway Epithelial Signaling: Implications for Lung Diseases. Beyond Graft Rejection . Lung.